Your browser is no longer supported. Please, upgrade your browser.
Settings
ILMN Illumina, Inc. daily Stock Chart
ILMN [NASD]
Illumina, Inc.
IndexS&P 500 P/E55.74 EPS (ttm)5.63 Insider Own0.40% Shs Outstand150.67M Perf Week-4.66%
Market Cap47.25B Forward P/E49.20 EPS next Y6.37 Insider Trans-15.30% Shs Float146.40M Perf Month-1.86%
Income834.00M PEG2.44 EPS next Q1.35 Inst Own91.40% Short Float1.76% Perf Quarter-10.63%
Sales3.24B P/S14.57 EPS this Y89.40% Inst Trans-0.63% Short Ratio2.31 Perf Half Y9.74%
Book/sh23.83 P/B13.16 EPS next Y10.93% ROA11.70% Target Price361.56 Perf Year44.81%
Cash/sh22.49 P/C13.94 EPS next 5Y22.80% ROE21.90% 52W Range207.51 - 372.61 Perf YTD43.52%
Dividend- P/FCF41.59 EPS past 5Y39.20% ROI9.90% 52W High-15.84% Beta1.04
Dividend %- Quick Ratio2.20 Sales past 5Y19.10% Gross Margin69.50% 52W Low51.12% ATR12.61
Employees6200 Current Ratio2.50 Sales Q/Q19.50% Oper. Margin28.30% RSI (14)44.18 Volatility3.56% 3.71%
OptionableYes Debt/Eq0.56 EPS Q/Q21.30% Profit Margin21.10% Rel Volume0.89 Prev Close310.89
ShortableYes LT Debt/Eq0.25 EarningsJan 22 AMC Payout0.00% Avg Volume1.12M Price313.58
Recom1.90 SMA20-3.40% SMA50-1.87% SMA2005.33% Volume992,303 Change0.87%
Oct-09-18Initiated UBS Neutral
Aug-07-18Upgrade Morgan Stanley Underweight → Equal-Weight
Jul-31-18Reiterated Canaccord Genuity Buy $330 → $340
Feb-05-18Upgrade Citigroup Neutral → Buy
Jan-31-18Upgrade First Analysis Sec Equal-Weight → Overweight $277
Jan-05-18Initiated BTIG Research Neutral
Jan-05-18Downgrade William Blair Outperform → Mkt Perform
Jan-02-18Upgrade Wells Fargo Market Perform → Outperform
Oct-25-17Upgrade Robert W. Baird Neutral → Outperform $184 → $228
Oct-23-17Upgrade Janney Sell → Neutral
Oct-23-17Upgrade Deutsche Bank Hold → Buy $195 → $250
Sep-26-17Resumed Goldman Neutral $200
Aug-07-17Upgrade Canaccord Genuity Hold → Buy $170 → $215
Aug-02-17Upgrade First Analysis Sec Underweight → Equal-Weight
Apr-26-17Reiterated Cantor Fitzgerald Neutral $155 → $170
Mar-20-17Upgrade Leerink Partners Mkt Perform → Outperform
Feb-01-17Reiterated UBS Buy $180 → $185
Jan-18-17Initiated Deutsche Bank Hold $160
Jan-10-17Upgrade BofA/Merrill Neutral → Buy
Jan-06-17Upgrade CL King Neutral → Buy
Dec-17-18 09:05AM  Here's Why You Should Buy Express Scripts (ESRX) Stock Now Zacks
Dec-14-18 10:25AM  AMAG to Acquire Ciraparantag Maker Perosphere Pharmaceuticals Zacks
06:43AM  Here's Why You Should Hold Allscripts Stock in Your Portfolio Zacks
Dec-13-18 07:32AM  Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? Zacks
Dec-12-18 01:51PM  10 Stocks That Can Move Higher Whatever Happens InvestorPlace
09:30AM  Is Illumina (ILMN) Outperforming Other Medical Stocks This Year? Zacks
08:16AM  BD Gets Enterprise Level Cybersecurity Assessment From UL Zacks
Dec-10-18 05:06PM  Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Pacific Biosciences of California, Inc. (PACB) on Behalf of Stockholders and Encourages PACB Investors to Contact the Firm GlobeNewswire
08:53AM  Here's Why Investors Should Hold Masimo (MASI) Stock Now Zacks
08:36AM  Illumina (ILMN) Takes Part in NIH Program With Genotype Launch Zacks
Dec-09-18 09:00AM  2 Fantastic Stocks You Can Buy to Profit From Huge Healthcare Megatrends Motley Fool
Dec-06-18 04:05PM  Illumina Announces a New Genotyping Array and Scientific Contribution to Three Genome Centers to Support the All of Us Research Program Business Wire
10:31AM  Patterson Companies (PDCO) Q2 Earnings Beat, Revenues Miss Zacks
08:44AM  Here's Why You Should Hold Pacific Biosciences (PACB) Now Zacks
Dec-05-18 09:34AM  HealthEquity (HQY) Earnings & Revenues Beat Estimates in Q3 Zacks
Dec-03-18 09:22AM  Illumina, Douglas Dynamics, Amazon, JPMorgan and Apple highlighted as Zacks Bull and Bear of the Day Zacks
Dec-02-18 01:15PM  Youll soon be able to get a DNA test for $100 heres the company behind the breakthrough MarketWatch
08:17AM  3 Terrific Reasons to Buy Illumina Stock in December Motley Fool
Nov-30-18 05:45PM  Illumina (ILMN) Stock Sinks As Market Gains: What You Should Know Zacks
Nov-29-18 04:25PM  IBD 50 Stock Breaks Out Amid Boost For Medical Research Stocks Investor's Business Daily
08:45AM  Veeva Systems (VEEV) Q3 Earnings & Revenues Beat Estimates Zacks
Nov-27-18 04:23PM  Top Stock Picks for the Week of November 26th Zacks
08:06AM  PerkinElmer's Vanadis NIPT CE Mark Boosts Prenatal Prospects Zacks
Nov-25-18 11:35AM  Do Hedge Funds Love Illumina, Inc. (NASDAQ:ILMN)? Insider Monkey
Nov-23-18 09:45AM  Medtronic's Deal With Nutrino Health to Boost Diabetes Arm Zacks
08:45AM  Medtronic Gets Health Canada License for Visualase System Zacks
08:30AM  Zacks.com highlights: Crocs, Illumina, Twitter, Vocera Communications and Cardtronics Zacks
Nov-22-18 09:30AM  Illumina (ILMN) Up 7% Since Last Earnings Report: Can It Continue? Zacks
08:28AM  Insulet's (PODD) Omnipod DASH System Now ISO 27001 Certified Zacks
Nov-21-18 08:12AM  Boston Scientific's (BSX) $4.2B Buyout to Augment PI Business Zacks
08:10AM  Bet on 5 Stocks With Strong Earnings Beat Potential Zacks
Nov-20-18 02:37PM  Medtronic (MDT) Tops Q2 Earnings on Strong Segmental Growth Zacks
Nov-18-18 06:30AM  3 Healthcare Stocks That Have a Killer Advantage Motley Fool
Nov-16-18 04:59PM  Better Buy: EXACT Sciences Corporation vs. Illumina Motley Fool
08:35AM  Here's Why You Should Invest in Illumina (ILMN) Stock Now Zacks
Nov-15-18 10:02AM  Pacific Biosciences Offers Insights on Aedes aegypti Genome Zacks
Nov-14-18 05:45PM  Illumina (ILMN) Dips More Than Broader Markets: What You Should Know Zacks
02:26PM  Is This the Real Reason Illumina Acquired Pacific Biosciences? Motley Fool
01:59PM  Here's Why Illumina's $1.2 Billion Acquisition Makes Sense Motley Fool
Nov-13-18 04:05PM  Illumina to Webcast Upcoming Investor Conference Presentations Business Wire
02:32PM  Despite Lofty Price, Illumina May Still Be a Buy GuruFocus.com
12:25PM  Speedy Medtech: Why These Fast-Growing Stocks Should Be On Your Radar Investor's Business Daily
Nov-12-18 11:51AM  3 DNA Stocks That Are on the Uptrend InvestorPlace -5.73%
11:07AM  Illumina's Growth Shows No Signs of Slowing Down GuruFocus.com
08:54AM  Is Illumina (ILMN) a Great Growth Stock? Zacks
Nov-11-18 06:33AM  Here's My Top Stock to Buy in November Motley Fool
Nov-10-18 09:54AM  Biotech stocks have been hit hard here are ones analysts like best for a rebound MarketWatch
Nov-09-18 09:01AM  3 Growth Stocks Healthcare Investors Should Buy Now Motley Fool
08:56AM  The Zacks Analyst Blog Highlights: DXP Enterprises, Bristol-Myers Squibb, EnPro Industries, Illumina and NetApp Zacks
Nov-08-18 04:55PM  Why Alkermes' Depression Drug Stumbled, and How Illumina Plans to Profit From M&A Motley Fool
09:30AM  Is Illumina (ILMN) Outperforming Other Medical Stocks This Year? Zacks
Nov-07-18 10:09AM  Pacific Biosciences (PACB) Reports Q3 Loss, Revenues Fall Y/Y Zacks +6.18%
09:34AM  Illumina (ILMN) Inks $1.2B Deal to Buy Pacific Biosciences Zacks
Nov-06-18 05:45PM  Illumina (ILMN) Stock Sinks As Market Gains: What You Should Know Zacks
Nov-05-18 02:07PM  Twist Bioscience IPO: What Investors Need to Know Motley Fool
08:06AM  Zacks.com highlights: Illumina, Molina Healthcare, Twitter, Vocera Communications and WNS Holdings Zacks
08:00AM  9 Innovation-Driven Large Caps Poised for Rapid Growth Investopedia
04:05AM  Edited Transcript of ILMN earnings conference call or presentation 23-Oct-18 9:00pm GMT Thomson Reuters StreetEvents
Nov-04-18 05:31PM  Where Will Illumina, Inc. Be in 10 Years? Motley Fool
Nov-03-18 02:01PM  Here's Why Illimuna Just Bought Its Biggest Competitor Motley Fool
Nov-02-18 04:28PM  Why Newell Brands, VeriSign, and Pacific Biosciences of California Jumped Today Motley Fool
11:00AM  Why Pacific Biosciences of California Stock Is Skyrocketing Today Motley Fool
08:40AM  Recent Analysis Shows Huntsman, Illumina, Alaska Air Group, Hilton Grand Vacations, Seaspan, and Honda Motor Co. Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
08:32AM  Illumina Buys Rival Pacific Biosciences In $1.2B Deal Benzinga
08:13AM  Go Beyond Earnings Growth, Bet on Beat With 5 Stocks Zacks
08:01AM  The Daily Biotech Pulse: Illumina Snaps Up Pacific Bioscience, Thumbs Down For Alkermes Depressive Disorder Drug Benzinga
06:01AM  Pacific Biosciences of California Reports a Dismal Quarter -- and a Delightful Acquisition Motley Fool
Nov-01-18 05:49PM  Illumina Inc. to buy Menlo Park-based biotech firm for $1.2 billion American City Business Journals
05:13PM  DNA sequencing giant Illumina just bought rival Pac Bio for $1.2 billion here's why CNBC
05:07PM  Illumina to buy rival Pacific Biosciences in $1.2 bln deal Reuters
04:18PM  Gene sequencing company Illumina to buy Pacific Biosciences in $1.2 billion deal Reuters
04:16PM  Illumina to acquire Pacific Biosciences for $1.2 billion in cash MarketWatch
04:13PM  Gene sequencing company Illumina to buy Pacific Biosciences in $1.2 bln deal Reuters
04:02PM  Illumina to Acquire Pacific Biosciences for Approximately $1.2 Billion, Broadening Access to Long-Read Sequencing and Accelerating Scientific Discovery Business Wire
01:56PM  Helix Launches the New DNA Discovery Kit PR Newswire
Oct-31-18 08:00AM  Today's Research Reports on Trending Tickers: Exact Sciences and Illumina ACCESSWIRE
Oct-30-18 04:05PM  Illumina Launches TruSight Oncology 500 to Power Comprehensive, Accurate, Pan-Cancer Tumor Profiling Business Wire
Oct-29-18 05:45PM  Illumina (ILMN) Dips More Than Broader Markets: What You Should Know Zacks
Oct-26-18 12:10PM  Our Top Stock Ideas in Silicon Valleys Biggest Bet in Healthcare Motley Fool
Oct-25-18 10:47PM  Silicon Valley's Big Bet in Healthcare Motley Fool
07:41AM  The Zacks Analyst Blog Highlights: Procter & Gamble, Philip Morris, Honeywell, Lockheed and Illumina Zacks
Oct-24-18 12:23PM  Top Analyst Reports for Procter & Gamble, Philip Morris & Honeywell Zacks -7.74%
09:55AM  Illumina (ILMN) Beats Earnings and Revenue Estimates in Q3 Zacks
09:12AM  [$$] Stocks to Watch: Boeing, AT&T, UPS, Capital One, and More The Wall Street Journal
07:48AM  The Daily Biotech Pulse: Illumina's Strong Q3, Celgene's Positive Cancer Drug Trial, Proteostasis Offering Benzinga
06:01AM  lllumina Inc. Posts Highest Sequencing System Sales in 3 Years Motley Fool
Oct-23-18 09:13PM  Illumina Inc (ILMN) Q3 2018 Earnings Conference Call Transcript Motley Fool
07:28PM  Illumina Earnings, Revenue beat in Q3 Investing.com
05:36PM  This IBD 50 Medical Stock Just Crushed Third-Quarter Expectations Investor's Business Daily
05:20PM  Illumina (ILMN) Q3 Earnings and Revenues Top Estimates Zacks
04:13PM  Illumina: 3Q Earnings Snapshot Associated Press
04:05PM  Illumina Reports Financial Results for Third Quarter of Fiscal Year 2018 Business Wire
09:30AM  Is Illumina (ILMN) Outperforming Other Medical Stocks This Year? Zacks
07:58AM  Q3 Earnings Preview For Illumina Benzinga
Oct-22-18 09:00AM  Why Illumina (ILMN) Might Surprise This Earnings Season Zacks
Oct-19-18 09:30AM  AMGN or ILMN: Which Is the Better Value Stock Right Now? Zacks
Oct-17-18 05:45PM  Illumina (ILMN) Gains As Market Dips: What You Should Know Zacks
04:15PM  Amazon, Illumina among Wall Street analysts' favorite stocks to buy on this market dip CNBC
07:50AM  Can Solid Overall Growth Drive Illumina (ILMN) Q3 Earnings? Zacks
Oct-16-18 10:31AM  Illumina (ILMN) Q3 Earnings Preview: What's in the Cards? Zacks
Illumina, Inc. provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array. The company also provides various library preparation and sequencing kits to simplify workflows and accelerate analysis; and genome sequencing, genotyping, and noninvasive prenatal testing, as well as products support services. It serves genomic research centers, academic institutions, government laboratories, and hospitals; and pharmaceutical, biotechnology, agrigenomics, and commercial molecular diagnostic laboratories, as well as consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. It operates in North America, Europe, Latin America, the Asia-Pacific region, the Middle East, and South Africa. The company has a strategic partnership with Loxo Oncology, Inc. to develop and commercialize a multi-gene panel for broad tumor profiling; and strategic collaboration with Bristol-Myers Squibb Company. Illumina, Inc. was founded in 1998 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
FLATLEY JAY TDirectorDec 12Sale334.133,3001,102,629371,559Dec 13 07:26 PM
OSTADAN OMEADEVP Ops, Products, StrategyDec 10Sale321.50644207,04621,613Dec 12 01:59 PM
Stapley MarcEVP Strategy & Corp DevelopmtDec 06Sale329.691,000329,6956,957Dec 07 05:17 PM
EPSTEIN ROBERT SDirectorDec 03Option Exercise51.171,00051,1706,101Dec 04 09:03 PM
EPSTEIN ROBERT SDirectorDec 03Sale343.571,345462,1024,756Dec 04 09:03 PM
Dadswell CharlesSr VP & General CounselDec 03Sale343.57566194,4615,606Dec 04 09:01 PM
deSouza Francis APresident and CEODec 03Sale345.903,0001,037,68863,643Dec 04 09:02 PM
FLATLEY JAY TDirectorNov 28Sale321.803,3001,061,940373,410Nov 30 04:24 PM
OSTADAN OMEADEVP Ops, Products, StrategyNov 23Sale306.74644197,54122,257Nov 27 04:39 PM
FLATLEY JAY TDirectorNov 14Sale312.503,3001,031,250376,710Nov 16 04:09 PM
Ronaghi MostafaSr VP & CTONov 12Option Exercise37.0410,000370,40079,612Nov 14 05:44 PM
Ronaghi MostafaSr VP & CTONov 12Sale314.6310,0003,146,33769,612Nov 14 05:44 PM
Stapley MarcEVP Strategy & Corp DevelopmtNov 07Sale336.681,000336,6806,957Nov 09 04:23 PM
Van Oene MarkSVP Chief Commercial OfficerNov 05Option Exercise29.446,000176,64017,126Nov 07 05:05 PM
Van Oene MarkSVP Chief Commercial OfficerNov 05Sale326.116,8352,228,95010,291Nov 07 05:05 PM
EPSTEIN ROBERT SDirectorNov 01Option Exercise51.171,00051,1706,447Nov 02 05:01 PM
EPSTEIN ROBERT SDirectorNov 01Sale311.861,346419,7645,101Nov 02 05:01 PM
deSouza Francis APresident and CEONov 01Sale310.852,100652,78870,235Nov 02 05:03 PM
FLATLEY JAY TDirectorOct 24Sale310.583,3001,024,914382,304Oct 26 04:35 PM
Ronaghi MostafaSr VP & CTOOct 10Option Exercise37.0410,000370,40080,805Oct 12 04:37 PM
Ronaghi MostafaSr VP & CTOOct 10Sale311.8410,0003,118,42470,805Oct 12 04:37 PM
FLATLEY JAY TDirectorOct 10Sale321.583,3001,061,214385,604Oct 12 04:35 PM
EPSTEIN ROBERT SDirectorOct 01Option Exercise51.171,00051,1706,793Oct 03 04:17 PM
deSouza Francis APresident and CEOOct 01Sale369.612,100776,18372,335Oct 03 04:20 PM
EPSTEIN ROBERT SDirectorOct 01Sale369.151,346496,8765,447Oct 03 04:17 PM
FLATLEY JAY TDirectorSep 26Sale360.813,3001,190,673388,904Sep 28 05:29 PM
FLATLEY JAY TDirectorSep 12Sale351.663,3001,160,478392,204Sep 14 09:25 PM
Ronaghi MostafaSr VP & CTOSep 10Option Exercise37.0410,000370,40080,805Sep 11 05:49 PM
Ronaghi MostafaSr VP & CTOSep 10Sale347.0710,0003,470,70970,805Sep 11 05:49 PM
EPSTEIN ROBERT SDirectorSep 07Option Exercise51.171,00051,1707,139Sep 11 05:45 PM
EPSTEIN ROBERT SDirectorSep 07Sale345.141,346464,5585,793Sep 11 05:45 PM
deSouza Francis APresident and CEOSep 04Sale353.662,100742,68674,435Sep 06 06:26 PM
Van Oene MarkSVP Chief Commercial OfficerSep 04Sale354.181,091386,41011,126Sep 06 06:09 PM
Stapley MarcEVP Strategy & Corp DevelopmtSep 04Sale352.051,000352,0548,516Sep 06 08:22 PM
Ronaghi MostafaSr VP & CTOAug 10Option Exercise37.0410,000370,40080,805Aug 14 04:07 PM
Ronaghi MostafaSr VP & CTOAug 10Sale331.3910,0003,313,86170,805Aug 14 04:07 PM
OSTADAN OMEADEVP Ops, Products, StrategyAug 02Sale320.701,334427,81424,484Aug 06 08:11 PM
Stapley MarcEVP Strategy & Corp DevelopmtAug 02Sale324.801,000324,7987,516Aug 06 08:10 PM
deSouza Francis APresident and CEOAug 01Sale327.412,100687,55576,535Aug 03 03:03 PM
EPSTEIN ROBERT SDirectorJul 23Sale311.15500155,5756,139Jul 24 07:21 PM
deSouza Francis APresident and CEOJul 12Sale300.003,300990,00078,635Jul 13 02:39 PM
Ronaghi MostafaSr VP & CTOJul 10Option Exercise37.047,500277,80078,496Jul 12 07:39 PM
Ronaghi MostafaSr VP & CTOJul 10Sale288.897,5002,166,70170,996Jul 12 07:39 PM
deSouza Francis APresident and CEOJul 02Sale276.142,100579,88782,271Jul 03 06:20 PM
EPSTEIN ROBERT SDirectorJun 21Sale288.45500144,2256,639Jun 22 07:12 PM
Ronaghi MostafaSr VP & CTOJun 11Option Exercise28.4510,500298,72581,496Jun 13 06:21 PM
Stapley MarcEVP Strategy & Corp DevelopmtJun 11Sale285.181,446412,3648,516Jun 13 06:24 PM
Ronaghi MostafaSr VP & CTOJun 11Sale284.8310,5002,990,75970,996Jun 13 06:21 PM
OSTADAN OMEADEVP Ops, Products, StrategyJun 01Sale274.611,335366,60425,818Jun 04 08:57 PM
deSouza Francis APresident and CEOJun 01Sale272.912,100573,10784,371Jun 04 08:54 PM
EPSTEIN ROBERT SDirectorMay 21Sale271.00500135,5006,588May 22 05:25 PM
EASTHAM KARINDirectorMay 21Sale269.801,000269,80212,288May 22 05:23 PM
Ronaghi MostafaSr VP & CTOMay 16Option Exercise28.4510,000284,50080,996May 18 07:39 PM
Ronaghi MostafaSr VP & CTOMay 16Sale267.7110,0002,677,13570,996May 18 07:39 PM
FLATLEY JAY TDirectorMay 14Sale268.001,460391,2804,000May 16 09:40 PM
deSouza Francis APresident and CEOMay 14Sale268.632,100564,12486,471May 16 09:37 PM
OSTADAN OMEADEVP Ops, Products, StrategyMay 02Sale242.601,314318,77627,153May 04 06:53 PM
BOWMAN A BLAINEDirectorMay 01Option Exercise55.143,000165,42619,868May 03 06:23 PM
BOWMAN A BLAINEDirectorMay 01Sale241.453,000724,33616,868May 03 06:23 PM
Van Oene MarkSVP Chief Commercial OfficerApr 12Sale238.481,400333,87212,217Apr 13 07:30 PM
Dadswell CharlesSr VP & General CounselApr 03Sale230.9111626,7867,875Apr 04 07:32 PM
BOWMAN A BLAINEDirectorApr 02Option Exercise44.513,000133,53019,868Apr 04 07:29 PM
BOWMAN A BLAINEDirectorApr 02Sale230.133,000690,38316,868Apr 04 07:29 PM
ARNOLD FRANCESDirectorMar 15Sale252.2625063,06510,189Mar 15 07:56 PM
ARNOLD FRANCESDirectorMar 08Sale241.5025060,37510,439Mar 08 07:50 PM
Stapley MarcEVP Strategy & Corp DevelopmtMar 06Sale233.642,000467,28813,787Mar 08 07:45 PM
EASTHAM KARINDirectorMar 05Option Exercise71.092,000142,18015,288Mar 06 07:17 PM
EASTHAM KARINDirectorMar 05Sale229.372,000458,73513,288Mar 06 07:17 PM
Dadswell CharlesSr VP & General CounselMar 05Sale227.1714532,9407,991Mar 06 07:13 PM
OSTADAN OMEADEVP Ops, Products, StrategyMar 02Sale222.661,329295,91628,467Mar 05 09:03 PM
BOWMAN A BLAINEDirectorMar 01Option Exercise44.513,000133,53019,868Mar 05 08:12 PM
BOWMAN A BLAINEDirectorMar 01Sale227.013,000681,02816,868Mar 05 08:12 PM
EPSTEIN ROBERT SDirectorFeb 28Sale231.2525057,8137,088Mar 02 07:06 PM
Van Oene MarkSVP Chief Commercial OfficerFeb 16Sale228.851,408322,22113,617Feb 20 09:26 PM
Van Oene MarkSVP Chief Commercial OfficerFeb 15Option Exercise0.002,124015,760Feb 20 09:26 PM
Stapley MarcEVP Strategy & Corp DevelopmtFeb 15Option Exercise0.006,257032,430Feb 20 09:23 PM
Ronaghi MostafaSr VP & CTOFeb 15Option Exercise0.004,740072,785Feb 20 09:18 PM
OSTADAN OMEADEVP Ops, Products, StrategyFeb 15Option Exercise0.006,257032,355Feb 20 09:16 PM
FLATLEY JAY TDirectorFeb 15Option Exercise0.0026,5420413,706Feb 20 09:13 PM
deSouza Francis APresident and CEOFeb 15Option Exercise0.0010,238092,990Feb 20 09:10 PM
Dadswell CharlesSr VP & General CounselFeb 15Option Exercise0.003,79209,455Feb 20 09:07 PM
Stapley MarcEVP Strategy & Corp DevelopmtFeb 06Sale216.872,000433,74126,052Feb 08 06:23 PM
Dadswell CharlesSr VP & General CounselFeb 05Sale221.451,610356,5355,581Feb 05 07:07 PM
BOWMAN A BLAINEDirectorFeb 01Option Exercise44.513,000133,53019,868Feb 05 07:05 PM
BOWMAN A BLAINEDirectorFeb 01Sale230.823,000692,44816,868Feb 05 07:05 PM
EPSTEIN ROBERT SDirectorJan 29Option Exercise51.171,00051,1708,588Jan 30 08:36 PM
EPSTEIN ROBERT SDirectorJan 29Sale244.181,250305,2257,338Jan 30 08:36 PM
Stapley MarcEVP Strategy & Corp DevelopmtJan 17Sale242.332,000484,66728,315Jan 18 07:01 PM
FLATLEY JAY TDirectorJan 16Sale243.7215,0003,655,763437,899Jan 18 06:50 PM
Dadswell CharlesSr VP & General CounselJan 03Sale224.5014532,5537,411Jan 04 06:53 PM
FLATLEY JAY TDirectorJan 02Sale223.4020,0004,468,090452,899Jan 03 09:16 PM
EPSTEIN ROBERT SDirectorDec 29Option Exercise51.171,00051,1708,838Jan 02 08:36 PM
EPSTEIN ROBERT SDirectorDec 29Sale217.381,250271,7257,588Jan 02 08:36 PM
FLATLEY JAY TDirectorDec 19Sale215.4820,0004,309,502472,899Dec 21 08:03 PM